Roche In New Phase III Bet On MorphoSys' Anti-Amyloid Agent
Roche is taking a punt on a new Phase III trial with gantenerumab in patients with mild Alzheimer's despite ending one called SCarlet RoAD in similar patients just over two years ago.
Roche is taking a punt on a new Phase III trial with gantenerumab in patients with mild Alzheimer's despite ending one called SCarlet RoAD in similar patients just over two years ago.